Gemin X Pharmaceuticals to Present Data on Obatoclax at American Society of Hematology Annual Meeting

    Company's Lead Candidate to be Highlighted in Eight Abstract

    MALVERN, PA. & MONTREAL, QC, December 3 /CNW/ - Gemin X announced today
that results of several clinical and preclinical studies of its lead
anti-cancer candidate obatoclax (GX15-070) will be presented at the 49th
annual meeting of the American Society of Hematology (ASH) in Atlanta, GA.
Obatoclax is a novel, small molecule candidate in Phase 2 trials in multiple
cancer indications that is specifically designed to inhibit all relevant
members of the Bcl-2 protein family, a validated cancer target, restoring the
natural cell death process of apoptosis.

    "The presentation of multiple abstracts at ASH demonstrates the
therapeutic promise of obatoclax and provides us with additional important
information on the compound that will support its extensive clinical
development program," said Dr. Gordon Shore, Chief Scientific Officer and
Interim Chief Executive Officer of Gemin X. "These abstracts underscore
obatoclax's potential synergistic effects in combination with other
treatments, its utility in indications resistant to current therapies, its
ability to initiate apoptosis, and its activity in a variety of cancer types.
We believe that this emerging positive profile may position obatoclax as a
potential new therapeutic that may improve treatment outcomes for cancer

    Details on the abstractsbeing presented at ASH:

    Abstract Title:       Direct and Enhanced Cytotoxicity of the Bcl-2
                           Family Inhibitor GX15-070 on Rituximab-
                           Sensitive and Rituximab-Resistant B-NHL Clones.
                           Abstract No. 1402
    Poster Session Info:  Lymphoma: Pre-Clinical: Chemotherapy and
                           Biologic Agents I, Board # 556-I
                          Saturday, December 8 5:30 PM

    Abstract Title:       Bcl-2 Phosphorylation Modulates Sensitivity to
                           the BH3-Mimetic GX15-070 (Obatoclax) and
                           Reduces its Synergistic Interaction with
                           Bortezomib in Chronic Lymphocytic Leukemia
                           Cells. Abstract No. 3464
    Poster Session Info:  Molecular Response Determinants, Board # 683-III
                          Monday, December 10 5:00 PM

    Abstract Title:       GX15-070 and Bortezomib Induce Up-Regulation of
                           BH3 Single Domain Pro-Apoptotic Proteins Puma
                           and Noxa and is Associated with Synergistic
                           Anti-Tumor Activity in Rituximab-Sensitive,
                           Rituximab-Resistant Cell Lines (RSCL and RRCL),
                           and Primary Lymphoma Patient Specimens.
                           Abstract No. 1389
    Poster Session Info:  Lymphoma: Pre-Clinical: Chemotherapy and
                           Biologic Agents I, Board # 543-I
                          Saturday, December 8 5:30 PM

    Abstract Title:       Targeting 14-3-3 Sensitizes Native and Mutant
                           BCR-ABL to Inhibition with U0126, Rapamycin and
                           Bcl-2 Inhibitor GX15-070. Abstract No. 2920
    Poster Session Info:  Chronic Myeloid Leukemia: Biology and
                           Pathophysiology II, Board #139-III
                          Monday, December 10 5:00 PM

    Abstract Title:       A Phase 1 Trial of the Pan Bcl-2 Family
                           Inhibitor Obatoclax Mesylate (GX15-070) in
                           Combination with Bortezomib in Patients with
                           Relapsed/Refractory Mantle Cell Lymphoma:
                           Abstract No. 2569
    Poster Session Info:  New Agents and Treatment Approaches in Non-
                           Hodgkin Lymphoma, Board #759-II
                          Sunday, December 9 6:00 PM

    Abstract Title:       A Phase II Trial of the Small Molecule Pan-Bcl-2
                           Family Inhibitor Obatoclax Mesylate (GX15-070)
                           Administered by a 24-h Continuous Infusion
                           Every 2 Weeks to Patients with Chronic
                           Idiopathic Myelofibrosis (CIMF). Abstract No.
    Poster Session Info:  Myeloproliferative Syndromes: Therapy, Board
                          Monday, December 10 5:00 PM

    Abstract Title:       A Phase I Trial of the Small Molecule Pan-Bcl-2
                           Family Inhibitor Obatoclax Mesylate (GX15-070)
                           Administered by Continuous Infusion for up to
                           Four Days to Patients with Hematological
                           Malignancies. Abstract No. 892
    Poster Session Info:  Acute Myeloid Leukemias: Therapy, Excluding
                           Transplantation I, Board #46-I
                          Saturday, December 8 5:30 PM

    Abstract Title:       The BH3-Mimetic Obatoclax Restores the Response
                           to Dexamethasone in Glucocorticoid-Resistant
                           ALL through Induction of Autophagy. Abstract
    Oral Session Info:    Simultaneous Session: Molecular Pharmacology:
                           Drug Resistance ,
                          Tuesday, December 11 7:45 AM

    About Obatoclax

    Obatoclax (GX15-070) is a small molecule indole bipyrrole drug compound
that was discovered and is being developed at Gemin X. The attractive safety
profile and mechanism of action of obatoclax offers the opportunity to treat
many forms of cancer as both a single agent and in combination with current
treatments. Obatoclax is currently being assessed in multiple Phase 2
company-sponsored clinical trials directed against multiple solid tumor and
hematologic malignancies. In addition to clinical activity in multiple
indications, obatoclax is generally well tolerated, and is without evidence of
immuno- and myelosuppression.

    About Gemin X

    Gemin X Pharmaceuticals, Inc., through its subsidiary Gemin X
Biotechnologies Inc., specializes in the discovery and development of
target-based novel cancer therapeutics. Gemin X's lead product, obatoclax
(GX15-070), is a small molecule, pan-inhibitor of Bcl-2 proteins and is
currently in Phase 2 clinical trials. Gemin X is also developing GMX1777, a
small molecule that targets cancer metabolism by a p53-independent mechanism.
Gemin X is privately held and is located in Malvern, Pennsylvania and
Montreal, Quebec. For additional information please visit Gemin X at

For further information:

For further information: MacDougall Biomedical Communications Jennifer
Greenleaf, 508-647-0209 or Gemin X Biotechnologies Inc. Diane Viens,
514-281-8989 ext.387

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890